Free Trial

argenx (ARGX) Stock Forecast & Price Target

$471.32
+4.76 (+1.02%)
(As of 07/19/2024 ET)

argenx - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 21 Wall Street analysts who have issued ratings for argenx in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 5 have given a hold rating, 15 have given a buy rating, and 1 has given a strong buy rating for ARGX.

Consensus Price Target

$533.47
13.19% Upside
High Forecast$641.00
Average Forecast$533.47
Low Forecast$408.00

According to the 21 analysts' twelve-month price targets for argenx, the average price target is $533.47. The highest price target for ARGX is $641.00, while the lowest price target for ARGX is $408.00. The average price target represents a forecasted upside of 13.19% from the current price of $471.32.

TypeCurrent Forecast
7/22/23 to 7/21/24
1 Month Ago
6/22/23 to 6/21/24
3 Months Ago
4/23/23 to 4/22/24
1 Year Ago
7/22/22 to 7/22/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
15 Buy rating(s)
14 Buy rating(s)
14 Buy rating(s)
18 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$533.47$520.68$528.16$520.33
Forecasted Upside13.19% Upside27.28% Upside26.16% Upside24.87% Upside
Get argenx Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter.

ARGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ARGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

argenx Stock vs. The Competition

TypeargenxMedical CompaniesS&P 500
Consensus Rating Score
2.81
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside13.19% Upside3,282.87% Upside10.07% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/17/2024HC Wainwright
3 of 5 stars
 Boost TargetBuy ➝ Buy$490.00 ➝ $504.00+7.08%
7/17/2024Wedbush
3 of 5 stars
 Reiterated RatingOutperform ➝ Outperform$519.00 ➝ $519.00+10.21%
7/12/2024Evercore ISI
2 of 5 stars
 Boost TargetOutperform ➝ Outperform$478.00 ➝ $533.00+15.44%
6/25/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$440.00 ➝ $480.00+8.94%
6/24/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$535.00 ➝ $607.00+40.57%
6/24/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$485.00 ➝ $500.00+14.82%
6/24/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$522.00 ➝ $535.00+35.63%
6/24/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$478.00 ➝ $542.00+37.40%
6/17/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Minter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
5/28/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$515.00 ➝ $510.00+39.29%
5/13/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$560.00 ➝ $500.00+34.23%
5/10/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Outperform ➝ Market Outperform$471.00 ➝ $468.00+25.62%
3/26/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSector Perform ➝ Sector Perform$402.00 ➝ $408.00+2.40%
3/1/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$505.00 ➝ $490.00+28.94%
2/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoveragePeer Perform
12/21/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetStrong-Buy ➝ Strong-Buy$580.00 ➝ $520.00+53.43%
12/20/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
12/12/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$612.00 ➝ $641.00+41.35%
11/29/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$610.00 ➝ $591.00+32.71%
10/2/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$605.00 ➝ $628.00+29.56%
7/28/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$545.00 ➝ $590.00+17.72%
7/24/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$480.00 ➝ $570.00+3.93%
6/15/2023Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSell
5/5/2023888
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
3/3/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$430.00 ➝ $435.00+25.00%
3/3/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$430.00 ➝ $435.00+26.07%
1/25/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$441.00 ➝ $458.00+19.73%
12/6/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight€405.00 ➝ €450.00
10/11/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 01:09 PM ET.

ARGX Forecast - Frequently Asked Questions

What is argenx's forecast for 2024?

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for argenx is $533.47, with a high forecast of $641.00 and a low forecast of $408.00.

Should I buy or sell argenx stock right now?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 5 hold ratings, 15 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARGX shares.

Does argenx's stock price have much upside?

According to analysts, argenx's stock has a predicted upside of 24.62% based on their 12-month stock forecasts.

What analysts cover argenx?
Do Wall Street analysts like argenx more than its competitors?

Analysts like argenx more than other "medical" companies. The consensus rating score for argenx is 2.81 while the average consensus rating score for "medical" companies is 2.72. Learn more on how ARGX compares to other companies.


This page (NASDAQ:ARGX) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners